Intravenous Iron Dosing for Iron Deficiency
For initial IV iron correction, administer 1000 mg as a single total dose infusion (or up to 1500 mg based on body weight and iron deficit), using formulations that allow high-dose administration such as ferric carboxymaltose (750-1000 mg), ferric derisomaltose (up to 1000-2000 mg), or low-molecular-weight iron dextran (up to 1000 mg). 1
Recommended Dosing Approach
The most recent expert consensus guidelines (2025) strongly support total dose infusion over multiple smaller doses 1. This approach:
- Reduces the number of infusion visits required
- Improves patient convenience and treatment adherence
- Achieves more complete iron repletion
- Decreases healthcare costs
Specific Formulation Dosing
Preferred high-dose formulations:
Ferric carboxymaltose (FCM): 750-1000 mg per infusion, maximum 1000 mg/week. Can give 750 mg × 2 doses one week apart OR 1000 mg as single dose. Infusion time: 15 minutes 2, 3, 4, 5
Ferric derisomaltose (FDI): Up to 1000-2000 mg as single infusion (20 mg/kg, no ceiling up to 2000 mg). Infusion time: ≥15 minutes for ≤1000 mg, ≥30 minutes for >1000 mg 3, 5
Low-molecular-weight iron dextran: 1000 mg as single infusion. Cost-effective option with comparable safety to newer formulations 3, 6, 5
Ferumoxytol: 510 mg × 2 doses OR 1020 mg single dose 7, 3, 5
Lower-dose formulations (require multiple visits):
- Iron sucrose: Maximum 200-500 mg per dose, requires multiple infusions 3, 4
- Ferric gluconate: Maximum 125 mg per dose 3, 4
Calculating Iron Deficit
Iron need is calculated based on body weight and hemoglobin levels, not ferritin or transferrin saturation 2. The typical iron deficit ranges from 1000-1580 mg in most patients 8, 9.
Common pitfall: Real-world data shows patients frequently receive less iron than their calculated deficit (mean dose 1244 mg vs. estimated need 1580 mg), resulting in persistent anemia in >65% of cases 9. Avoid underdosing—administer the full calculated deficit.
Timing and Monitoring
- Observe patients for 30 minutes post-infusion for adverse reactions 2
- Reassess iron status no sooner than 4 weeks after infusion (ideally 4-8 weeks) 1, 5
- Earlier testing yields spurious results due to circulating iron interfering with assays
- Hemoglobin should increase 1-2 g/dL within 4-8 weeks
- Target ferritin ≥50 ng/mL (≥100 ng/mL in inflammatory conditions)
Special Considerations
When IV iron is specifically indicated over oral iron 1:
- Rapid correction required
- Oral iron intolerance or gastrointestinal side effects
- Malabsorptive conditions (celiac disease, post-bariatric surgery, inflammatory bowel disease)
- Insufficient response to oral iron (Hb increase <1 g/dL or ferritin <30-50 ng/mL after 4-12 weeks)
- Chronic inflammatory conditions (heart failure, chronic kidney disease, cancer)
- Pregnancy (second and third trimesters) 1
Avoid ferric carboxymaltose for repeat dosing: FCM causes hypophosphatemia in 40-70% of adults, which can be prolonged and lead to fatigue and osteomalacia with repeated administration 2, 3, 5. Use alternative formulations for patients requiring ongoing iron replacement.
No routine premedication needed 1. Consider premedication or slower infusion rates only for:
- History of previous infusion reactions to IV iron
- Multiple severe drug allergies
- Inflammatory arthritis
Safety Profile
Modern IV iron formulations have low risk of serious adverse events 1. Most reactions are complement activation-related pseudo-allergy (CARPA), not true allergic reactions 3, 5, 10:
- For mild reactions: Stop infusion, restart after 15 minutes at slower rate
- Avoid diphenhydramine—side effects can mimic worsening reactions 3
- True iron allergy is extremely rare 3, 5
Evidence Quality
The 2025 Lancet Haematology consensus guidelines 1 represent the most current evidence-based recommendations with 96-100% expert consensus. These supersede older protocols using multiple small doses (e.g., 100 mg increments) that are no longer recommended for routine practice 11. Real-world data confirms that higher initial doses (≥1500 mg within 3 weeks) reduce need for additional treatments by 32% and decrease outpatient visits 8.